Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros












Base de datos
Intervalo de año de publicación
1.
J Oleo Sci ; 69(7): 751-757, 2020.
Artículo en Inglés | MEDLINE | ID: mdl-32612025

RESUMEN

The rising incidence of inflammatory bowel disease (IBD) in East Asian countries has necessitated the implementation of preventive methods in the form of dietary supplementation and changes in dietary habits. We have previously reported that dietary golden oyster mushroom (Pleurotus citrinopileatus) ethanol extract (GOMEE) suppresses intestinal inflammation in mouse models of IBD induced by dextran sulfate sodium salt (DSS). Here, we investigated the components of GOMEE that exert suppressive effects on colon inflammation in vivo and in vitro. The total lipid fraction was extracted from GOMEE, and the polar and neutral lipid fractions were subsequently separated via solvent fractionation. Mice were assigned to dietary groups-control, 1% total lipid, 1% polar lipid, or 1% neutral lipid diet-and fed the respective diets for one week; mice were administered 1.5% DSS in drinking water ad libitum for 20 days. Dietary supplementation with the total or polar lipid fraction alleviated DSS-induced chorionic crypt injury as determined by morphological observation, while dietary supplementation with the neutral lipid fraction did not produce such effects. In the in vitro study, using differentiated Caco-2 cells as the colon model, treatment with the total or polar lipid fraction suppressed cell decrease by lipopolysaccharide (LPS)-induced apoptosis whereas treatment with the neutral lipid fraction did not. Moreover, accumulation of glucosylceramide (GlcCer), a fungal sphingolipid, was observed in the intestinal cells after treatment with polar lipid fraction. These results suggest that the active components of GOMEE that suppress colon inflammation are polar lipids, especially GlcCer. The structure of mushroom GlcCer differs from that of the plant counterpart and is therefore expected to exert different food functions.


Asunto(s)
Apoptosis/efectos de los fármacos , Colon/metabolismo , Colon/patología , Enfermedades Inflamatorias del Intestino/tratamiento farmacológico , Fitoterapia , Pleurotus/química , Esfingolípidos/farmacología , Esfingolípidos/uso terapéutico , Animales , Células CACO-2 , Fraccionamiento Químico , Suplementos Dietéticos , Modelos Animales de Enfermedad , Glucosilceramidas , Humanos , Enfermedades Inflamatorias del Intestino/metabolismo , Masculino , Ratones Endogámicos BALB C , Esfingolípidos/aislamiento & purificación
2.
J Oleo Sci ; 66(12): 1337-1342, 2017.
Artículo en Inglés | MEDLINE | ID: mdl-29199207

RESUMEN

To determine the mechanism underlying the anti-inflammatory effects of plant sphingolipids, especially plant glucosylceramide (GlcCer), the effects of plant sphingolipids on inflammatory stress in differentiated Caco-2 cells were compared to those of a sphingolipid of animal origin, galactosylceramide (GalCer). Addition of GlcCer or GalCer suppressed cell injury caused lipopolysaccharide (LPS)- and TNF-α-induced inflammatory stress and induction of apoptosis in differentiated Caco-2 cells. There was no difference in the suppressive effect between GlcCer and GalCer. The inflammatory cytokines and chemokines induced by LPS were suppressed by GlcCer. GlcCer remained on the cell surface. The results of this study can be summarized as follows: 1) sphingolipids such as GlcCer have potent anti-inflammatory effects; 2) GlcCer suppresses LPS-induced production of cytokines and apoptosis; 3) sphingolipids may remain on the surface of cells, and 4) the chemical properties of sphingolipids may prevent the interaction between LPS and its receptor.


Asunto(s)
Antiinflamatorios , Galactosilceramidas/farmacología , Glucosilceramidas/farmacología , Plantas/química , Esfingolípidos/farmacología , Animales , Apoptosis/efectos de los fármacos , Células CACO-2 , Diferenciación Celular , Citocinas/metabolismo , Humanos , Mediadores de Inflamación/metabolismo , Receptores de Lipopolisacáridos/metabolismo , Lipopolisacáridos/efectos adversos , Lipopolisacáridos/metabolismo , Factor de Necrosis Tumoral alfa/efectos adversos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...